TECX

$31.48

Market ClosedAs of Mar 17, 8:00 PM UTC

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs).

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$31.48
Potential Upside
5%
Whystock Fair Value$33.05
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$591.09M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-37.82%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
26.26

Recent News

MarketBeat
Feb 25, 2026

Tectonic Therapeutic Spotlights TX2100 in HHT as First-in-Human Phase 1 Dosing Begins

Tectonic Therapeutic (NASDAQ:TECX) used a virtual key opinion leader (KOL) event to outline its strategy for hereditary hemorrhagic telangiectasia (HHT) and highlight early clinical progress for TX2100, an investigational APJ antagonist designed to treat bleeding driven by dysregulated angiogenesis.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 14, 2026

Daniel Lochner Bought 70% More Shares In Tectonic Therapeutic

Investors who take an interest in Tectonic Therapeutic, Inc. ( NASDAQ:TECX ) should definitely note that the Chief...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Dec 10, 2025

Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating

Tectonic Therapeutic, Inc. (NASDAQ:TECX) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. On November 18, LifeSci Capital reiterated a Buy rating on Tectonic Therapeutic, Inc. (NASDAQ:TECX) stock with a price target of $88. Tectonic Therapeutic, Inc. (NASDAQ:TECX) is a biotechnology company that focuses on the discovery and development of therapeutic […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Nov 22, 2025

Tectonic Therapeutic (NASDAQ:TECX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Oct 12, 2025

Bullish Tectonic Therapeutic Insiders Loaded Up On US$61.2m Of Stock

Multiple insiders secured a larger position in Tectonic Therapeutic, Inc. ( NASDAQ:TECX ) shares over the last 12...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.